AstraZeneca Forum

Beaufort's note published this morning is up on Research Tree... The aforementioned updates are mixed for AstraZeneca. The successful trial of Faslodex 500mg offers earlier treatment options to post-menopausal women with HR+ locally advanced or metastatic breast cancer. The drug has more than 10 years of clinical evidence and was recently approved by FDA for use in combination with palbociclib in the treatment of women with hormone-receptor-positive, humanepidermal-growth-factor-receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC). On the other hand, disapproval of AstraZeneca's new drug (ZS-9) for high potassium levels due to a manufacturing issue is a major setback. AstraZeneca paid US$2.7bn for ZS Pharma to gain access to the drug. Moreover, many of its drugs are in the development phase. AstraZeneca has been facing certain growth-related issues, as some of its key drugs are approaching patent expiry.

AlphaValue's published a note on AstraZeneca, out this morning on Research Tree: "AstraZeneca’s Q1 results came in behind our expectations with product sales growth of 1% to $5.6bn. Externalisation revenue (+78%) contributed $550m, leading to group sales of $6.1bn (+5%). NB All growth numbers at CER unless specific otherwise. Currency had a negative impact of 4% on group sales, which ended at 1% growth yoy. Higher-than-expected R&D spend (+11%) was offset to some extent by effective cost containment at COGS (-19%) and SG&A (-8%), culminating in reported operating profit of $1bn (+17%). Core operating..."

I liked this idea

Welcome to the new AstraZeneca stream forum! Messages posted in the AstraZeneca stream will be logged here for posterity.